❇️ **Evidence status:** No human or dedicated animal studies. All claims extrapolated from its parent compound, Semax.
❇️ What it is
Adamax is a synthetic modification of Semax, the Russian-developed nootropic peptide. Chemically it's written as Ac-MEHFPGP-adamantyl, sometimes described as N-Acetyl Semax Adamantane. It's occasionally called "Super Semax" in research circles.
❇️ How it works
The starting point is Semax, a fragment of the ACTH hormone (specifically the ACTH 4-7 region, sequence Met-Glu-His-Phe-Pro-Gly-Pro). Semax has decades of Russian clinical use and research behind it, mostly in stroke rehabilitation and cognitive function, and it's thought to work partly by raising BDNF.
Adamax adds two changes to that backbone. An acetyl group at one end slows enzymatic breakdown. An adamantane group, which is a rigid cage-shaped carbon structure, is attached at the other end. Adamantane is very fat-soluble, and the theory is that it helps the molecule cross cell membranes and the blood-brain barrier more readily, while also resisting degradation.
The result should, in theory, be a longer-lasting and more brain-penetrant version of Semax.
❇️ What the research shows
This is where honesty matters. There are no published human trials on Adamax specifically. There is no dedicated clinical dataset.
Essentially every claim made about Adamax is extrapolated from Semax research or from general work on adamantane-modified neurotrophic peptides. Those adamantane-peptide designs do have preclinical support for improving learning, neurogenesis, and synaptogenesis in animal models. But that's the compound class, not this compound.
The Semax foundation is more solid. The long-running Russian work, including Ashmarin's review of fifteen years of Semax design and study, reported that intranasal Semax affected working memory and attention, with effects described as lasting on the order of a day.
So: a well-studied parent compound, a chemically sensible modification, and no direct evidence.
❇️ Protocol data from the literature
There is no published clinical protocol. What exists are figures that circulate in the research and nootropics community, which should be treated as community convention rather than sourced data:
➡ **Route most commonly discussed:** Intranasal, as a solution or spray.
➡ **Community-reported range:** 200 to 300 mcg, once daily, sometimes split or doubled. Some sources describe 100 to 300 mcg per nostril.
➡ **Community-reported cycling:** 2 to 4 week blocks.
➡ **Reported half-life:** Figures around 8 to 10 hours appear in vendor and database listings, but I can't trace these to a published pharmacokinetic study.
Vials are often supplied at 5 mg or larger, which is a very large amount relative to those microgram figures, so dilution math matters.
❇️ Handling notes
Lyophilized powder reconstituted with bacteriostatic water. Yellowing or discoloration indicates oxidation. Persistent cloudiness or visible particles indicate degradation or contamination.
⚠️ Bottom line
A rational chemical design built on a real peptide, with no direct human or even dedicated animal data. Anyone writing or reading about it should be clear that the claims are inherited from Semax, not demonstrated for Adamax.